savings per year for using AUC24 Vancomycin Bayesian-Based Dosing
Paul E Sabourenkov, MBioinf, Robert C McLeay, PhD, 1599. AUC24 Vancomycin Bayesian-Based Dosing:Increasing Therapeutic Target Attainment with DecreasedTDM Cost, Open Forum Infectious Diseases, Volume 6,Issue Supplement_2, October 2019, Page S583, https://doi.org/10.1093/ofid/ofz360.1463
reduced length of hospital stay per patient using TDM guidance
Paul E Sabourenkov, MBioinf, Robert C McLeay, PhD, 1599. AUC24 Vancomycin Bayesian-Based Dosing: Increasing Therapeutic Target Attainment with DecreasedTDM Cost, Open Forum Infectious Diseases, Volume 6,Issue Supplement_2, October 2019, Page S583, https://doi.org/10.1093/ofid/ofz360.1463
savings of malpractice claims due to preventable inpatient ADEs
Rothschild JM, Federico FA, Gandhi TK, Kaushal R,Williams DH, Bates DW. Analysis of Medication-Related Malpractice Claims: Causes, Preventability, and Costs. Arch Intern Med. 2002;162(21):2414–2420.
doi:10.1001/archinte.162.21.2414
up to
in benefit-to-cost from using a TDM software (aminoglycosides)
Schumacher GE, Barr JT. Economic and outcome issues for therapeutic drug monitoring in medicine. TherDrug Monit. 1998;20(5):539‐542.
doi:10.1097/00007691-199810000-00016
up to
savings in preventable ADEs per patient
Rothschild JM, Federico FA, Gandhi TK, Kaushal R, Williams DH, Bates DW. Analysis of Medication-Related Malpractice Claims: Causes, Preventability, and Costs. Arch Intern Med. 2002;162(21):2414–2420.
doi:10.1001/archinte.162.21.2414
reduction in the incidence of nephrotoxicity from using a TDM software (aminoglycosides)
van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA,Vinks AA. Impact of goal-oriented and model-basedclinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. TherDrug Monit. 1999;21(1):63‐73.
doi:10.1097/00007691-199902000-00010
Try PrecisePK precision dosing software free for 60 days